All
Expert Discusses Exciting Advancements in Treating GI Cancers
January 8th 2018The role of precision medicine has become a significant area of study, specifically with genomics and liquid biopsies. With the introduction of next-generation sequencing and an improvement in the understanding of molecular alterations, treatments for patients have begun to be individualized.
Popular Myeloma Drug Associated With Higher Rates of Heart Toxicity
January 5th 2018A drug commonly used to treat patients with multiple myeloma may lead to an increased risk of cardiovascular events such as heart attacks, according to recent research conducted at the Abramson Cancer Center of the University of Pennsylvania.
Inner-Ear Buildup of Cisplatin May Cause Hearing Loss
January 5th 2018“As the population of cancer survivors continues to grow, so does the importance of addressing the long-term sequelae of cancer treatment,” the authors wrote. “This hearing loss can result in multifaceted decrease in quality of life, and in pediatric patients it can impact social and academic development.”
Patients With Brain Tumors Face Late Hospice Enrollment and Utilization
January 4th 2018Adequate end-of-life care derives a variety of benefits for both patients and their families, including less invasive and ineffective intervention and less financial burden, said study author Justin Jordan, M.D., MPH, clinical director of the Pappas Center for Neuro-Oncology at Massachusetts General Hospital (MGH) Cancer Center.
Kisqali Granted Breakthrough Therapy Designation for Breast Cancer Subset
January 4th 2018Kisqali (ribociclib) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) to be used in combination with tamoxifen or an aromatase inhibitor (AI) in the frontline treatment of pre- or perimenopausal women who have hormone receptor-positive HER2-negative advanced or metastatic breast cancer.
Adcetris Combination Granted Priority Review for Hodgkin Lymphoma Treatment
January 3rd 2018Adcetris (brentuximab vedotin) was granted a priority review to a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) to be used in combination with Adriamycin, vinblastine and dacarbazine (AVD) to treat patients with classical Hodgkin lymphoma in the frontline setting, according to Seattle Genetics, the company developing the drug.
Wishing Cancer Survivors a New Year With Fewer Fears
January 2nd 2018Some cancer survivors are good at getting on with life. Some of us remain timid about the prospect of life, even when a prognosis is good. A new year is a good time to try harder to seize the day, whatever the future is likely to bring.
FDA Grants Priority Review for Rare Neuroendocrine Tumor Treatment
January 2nd 2018The Food and Drug Administration (FDA) granted a priority review designation to a novel version of Azedra (iobenguane I-131), a radiopharmaceutical, to treat patients with malignant or recurrent pheochromocytoma or paraganglioma (PPGL).
Thyroid Cancer Survivors Diagnosed Before 40 At Higher Risk For Aging-Related Disease
December 31st 2017Patients diagnosed with thyroid cancer before the age of 40 appear to be at the highest risk for age-related diseases, including heart disease and diabetes, compared with their age-matched counterparts.
Facing the Responsibilities of the New Year
December 29th 2017The new year impacts breast cancer survivors in a vastly different ways than it does most people. Our resolutions, especially health-related resolutions, can be detrimental to our health if we don't keep them. This survivor shares her own chagrin at failing to keep some promises.